Latest News
The Ketogenic Diet: Why Long-Term Safety Deserves Greater Scrutiny
The ketogenic diet has transitioned from a highly specialized therapeutic intervention to a widely promoted dietary strategy for weight loss, metabolic health, inflammation, and, in some circles, cancer prevention or treatment. Its popularity has outpaced the strength...
Latest News
Receptor.AI and Sethera Partner on AI-Guided Peptide Drug Discovery
Receptor.AI and Sethera Therapeutics Form Integrated Discovery Alliance for AI-Guided Polymacrocyclic Peptide Medicines Collaboration combines Sethera's proprietary enzymatic polymacrocyclisation and trillion-scale encoded screening with Receptor.AI's physics-based...
Dual and Triple Agonists Explained: GLP-1, GIP and Glucagon
Obesity and diabetes medicine has moved a long way from the single-hormone era. Dual and triple agonists are engineered molecules that switch on two or three hormone receptors at once. They now dominate the late-stage pipeline, and the highest doses tested have...
Ziltivekimab ZEUS Trial: What the Null Result Means
The ziltivekimab ZEUS trial has produced one of the more instructive negative results in recent cardiovascular medicine. Novo Nordisk announced headline results on 31 July 2026 showing that its once-monthly interleukin-6 inhibitor ziltivekimab lowered inflammation...
How the Gut-Brain-Metabolism Axis Is Reshaping Targeted Therapy
For decades, the fields of oncology, neuroscience, and microbiology operated in distinct silos within therapeutic research and clinical practice. Modern drug discovery, however, is rapidly witnessing a paradigm shift toward systemic biology. Researchers increasingly...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026
The oral GLP-1 market has changed faster in the past six months than in the previous six years. Where once Rybelsus stood alone as the only GLP-1 pill available, patients and clinicians must now navigate three distinct oral products, each with a different molecule, a...
The Case for Agility: Why Biopharma Must Embrace Adaptive Trial Designs
For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has...
GSK’s $10.6 Billion Nuvalent Deal: Reshaping the Lung Cancer Drug Race
Two FDA decision dates, 18 September and 27 November, are now the most important dates on GSK's calendar. On 9 June 2026, the British pharmaceutical giant announced it had agreed to acquire Cambridge, Massachusetts-based Nuvalent for $10.6 billion in cash, securing...
FDA Drug Approval Decisions: June and July 2026
The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...
Importance of Targeted Radiotherapeutics in Treating CNS Cancers
Radiation therapy is one of the important tools in the fight against cancer. About 50% of all cancer patients receive radiation therapy. Few modalities have had the same lasting impact across such a broad range of tumor types. In central nervous system (CNS) oncology,...
How Compassion Protects Healthcare Workers from Empathy Fatigue
Working professionals know the feeling of being worn out at the end of a long, demanding day; however, burnout is considered a more intense, full-body breakdown resulting from longer-term exhaustion. Herbert Freudenberger, Ph.D., who coined the term burnout, defined...
Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO
When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...
Clinical Insight: The Future of Sensory-Based Therapeutics in Healthcare
The role of sensory systems in human health has long been established within biological and neuroscientific research. Olfactory, auditory, and tactile pathways are deeply integrated into the body’s regulatory networks, influencing emotional processing, cognitive...
Dementia Relief Through Silence and Brain Wave Modulation
In silence, the brain regenerates, growing new neurons in the hippocampus which is the cerebral center of memory, spatial navigation and emotional regulation (Kriste, Nicola, Kronenberg, Walker, Liu, & Kempermann, 2015). Silence has also been shown to be relaxing...
The Silent Epidemic: Workplace Bullying in Healthcare
Workplace Bullying in Healthcare and the Leadership Response Healthcare is one of the most demanding professional environments on earth. Clinicians make high-stakes decisions under pressure, routinely absorb the grief and trauma of others, and operate within systems...
Weekly News Roundup | 8 June 2026
Life science news 8 June 2026: ASCO delivers landmark oncology data, GSK achieves hepatitis B functional cure breakthrough, and Servier secures a $2.65 billion rare disease deal in a milestone week for the industry. Revolution Medicines presented full Phase 3 data for...
The Scaling Crisis in Cell and Gene Therapy
There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...
Foundayo vs Rybelsus: The Oral GLP-1 Guide for 2026
The oral GLP-1 market has changed faster in the past six months than in the previous six years. Where once Rybelsus stood alone as the only GLP-1 pill available, patients and clinicians must now navigate three distinct oral products, each with a different molecule, a...
The Case for Agility: Why Biopharma Must Embrace Adaptive Trial Designs
For decades, the landscape of clinical research was dominated by fixed, traditional trial designs. In these legacy studies, the primary objective was often maintaining a strict, unchanging protocol from inception to conclusion. But the landscape of modern medicine has...
GSK’s $10.6 Billion Nuvalent Deal: Reshaping the Lung Cancer Drug Race
Two FDA decision dates, 18 September and 27 November, are now the most important dates on GSK's calendar. On 9 June 2026, the British pharmaceutical giant announced it had agreed to acquire Cambridge, Massachusetts-based Nuvalent for $10.6 billion in cash, securing...
FDA Drug Approval Decisions: June and July 2026
The summer months at the United States Food and Drug Administration are typically among the busiest on the regulatory calendar, and 2026 is proving no exception. With a succession of high-profile FDA drug approval decisions concentrated in June and July 2026, the...
Importance of Targeted Radiotherapeutics in Treating CNS Cancers
Radiation therapy is one of the important tools in the fight against cancer. About 50% of all cancer patients receive radiation therapy. Few modalities have had the same lasting impact across such a broad range of tumor types. In central nervous system (CNS) oncology,...
How Compassion Protects Healthcare Workers from Empathy Fatigue
Working professionals know the feeling of being worn out at the end of a long, demanding day; however, burnout is considered a more intense, full-body breakdown resulting from longer-term exhaustion. Herbert Freudenberger, Ph.D., who coined the term burnout, defined...
Daraxonrasib Doubles Survival in Pancreatic Cancer at ASCO
When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...
Clinical Insight: The Future of Sensory-Based Therapeutics in Healthcare
The role of sensory systems in human health has long been established within biological and neuroscientific research. Olfactory, auditory, and tactile pathways are deeply integrated into the body’s regulatory networks, influencing emotional processing, cognitive...
Dementia Relief Through Silence and Brain Wave Modulation
In silence, the brain regenerates, growing new neurons in the hippocampus which is the cerebral center of memory, spatial navigation and emotional regulation (Kriste, Nicola, Kronenberg, Walker, Liu, & Kempermann, 2015). Silence has also been shown to be relaxing...
The Silent Epidemic: Workplace Bullying in Healthcare
Workplace Bullying in Healthcare and the Leadership Response Healthcare is one of the most demanding professional environments on earth. Clinicians make high-stakes decisions under pressure, routinely absorb the grief and trauma of others, and operate within systems...
Weekly News Roundup | 8 June 2026
Life science news 8 June 2026: ASCO delivers landmark oncology data, GSK achieves hepatitis B functional cure breakthrough, and Servier secures a $2.65 billion rare disease deal in a milestone week for the industry. Revolution Medicines presented full Phase 3 data for...
The Scaling Crisis in Cell and Gene Therapy
There are FDA-approved therapies on the market today that can permanently resolve a disease in a single administration, for a price of one to three million dollars. The reimbursement system responsible for covering that cost was built around medications that people...
Featured Articles
Further News
Biosimilar Approvals 2026: What’s Approved and What’s Next
The biosimilar market in 2026 is delivering on years of regulatory groundwork, and the numbers tell a striking story. Since the first US biosimilar was approved in 2015, the sector has generated more than $56 billion in healthcare savings, according to Cardinal...
Clinical Trials Roundup | 05 June 2026
Akeso and Summit Therapeutics’ ivonescimab plus chemotherapy delivers a statistically significant overall survival benefit over a PD-1 inhibitor plus chemotherapy control in the Phase 3 HARMONi-6 trial for previously untreated advanced squamous non-small cell lung...
ASCO 2026: The Five Results That Will Change Cancer Treatment
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from 29 May to 2 June in Chicago, drew more than 44,000 oncology professionals and delivered what many clinicians described as some of the most consequential trial data seen at the conference...
The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026
The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Why AI Alone Cannot Solve Healthcare’s Data Fragmentation Problem
Artificial intelligence is transforming healthcare at a remarkable pace. From clinical documentation and predictive analytics to patient engagement and operational automation, AI is being positioned as a powerful force for improving how care is delivered. But there is...
Without Better Benchmarks, AI Drug Discovery Risks Losing Its Way
Artificial intelligence is rapidly reshaping drug discovery. Machine learning models are now used to predict protein structures, design molecules, prioritize targets, and optimize clinical candidates. Investment is surging, publications are multiplying, and claims of...
Burning from the Inside Out: When Strong Values Become Burnout Risks
Is Burnout More Than Workload? Are external pressures the only drivers of burnout, or can self-perception and the manipulation of values also play a role? Burnout, nervous system regulation, and boundaries have become increasingly familiar concepts within...
The Sourcing Channel Moved East
A record year of out-licensing pulled the West's early pipeline sourcing toward Shanghai and Suzhou. The discount that started it is already being competed away. What outlasts it is a two-source model for global pharma innovation. For most of the past decade, a...
Parkinson’s Research Field is Approaching a Pivotal Moment
Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...
Base Editing vs CRISPR: What’s the Difference and Why Does it Matter?
In May 2026, a single intravenous infusion reduced LDL cholesterol by up to 62% in patients with a genetic condition that no statin could adequately control. No repeat dosing was required. No serious adverse events were reported. The therapy, VERVE-102, was not a...
Mental Wellness in Your 50s & 60s: Strength and Serenity Ahead
The fifth and sixth decades of life are often portrayed as a period of increased freedom, wisdom, and personal fulfilment. For many individuals, these years bring the anticipation of retirement, the opportunity to travel, deeper family connections through...
The Emerging Health Tech Driving Globalised Healthcare
Historically, healthcare has been reactive, defined largely by where a patient lives and what is available within their local system. That model is beginning to break down as healthcare becomes increasingly global. Patients are no longer confined to a single system,...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.